LLC linked to Parabilis director buys 12,500 shares
Parabilis Medicines, Inc. director-associated entity Apothecary Capital LLC made an open-market purchase of 12,500 shares of common stock at $20.00 per share on June 11, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Parabilis Medicines, Inc. director-associated entity Apothecary Capital LLC made an open-market purchase of 12,500 shares of common stock at $20.00 per share on June 11, 2026. The shares are held indirectly, with Alan Sebulsky disclaiming beneficial ownership except for any pecuniary interest.
Insider Trade Summary
Net Buyer: 12,500 shares
Net Buy
1 txn
Insider
SEBULSKY ALAN
Role
Director
Bought
12,500 shs ($250K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 12,500 | $20.00 | $250K |
Holdings After Transaction:
Common Stock — 12,500 shares (Indirect, By Apothecary Capital LLC)
Footnotes (1)
- F1. Represents shares held by Apothecary Capital LLC ("Apothecary Capital"). The Reporting Person is the managing member of Apothecary Capital and may be deemed to share voting, investment and dispositive power with respect to the securities held by Apothecary Capital. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Key Figures
Shares purchased: 12,500 shares
Purchase price: $20.00 per share
Shares held after trade: 12,500 shares
+3 more
6 metrics
Shares purchased
12,500 shares
Open-market purchase of common stock on June 11, 2026
Purchase price
$20.00 per share
Price for non-derivative common stock transaction
Shares held after trade
12,500 shares
Indirect holdings by Apothecary Capital LLC following transaction
Transaction code
P (purchase)
Non-derivative open-market or private transaction
Ownership type
Indirect (I)
Held by Apothecary Capital LLC, associated with Alan Sebulsky
Net buy direction
Net-buy of 12,500 shares
Transaction summary shows net-buy direction
Key Terms
open-market purchase, indirect ownership, pecuniary interest, Section 16
4 terms
open-market purchase financial
"The Form 4 shows an open-market acquisition of 12,500 shares of Parabilis Medicines common stock at $20.00 per share"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
indirect ownership financial
"The transaction was reported as an indirect holding through Apothecary Capital LLC associated with director Alan Sebulsky"
pecuniary interest financial
"except to the extent of his pecuniary interest therein, if any"
Section 16 regulatory
"The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Parabilis Medicines (PBLS) report in this Form 4?
Parabilis Medicines reported an open-market purchase of 12,500 shares of common stock at $20.00 per share. The transaction was reported as an indirect holding through Apothecary Capital LLC associated with director Alan Sebulsky.
Was the Parabilis Medicines (PBLS) insider trade a purchase or a sale?
The reported insider trade was a purchase. The Form 4 shows an open-market acquisition of 12,500 shares of Parabilis Medicines common stock at $20.00 per share, categorized as a non-derivative transaction and coded as a purchase (P).
How is Alan Sebulsky’s ownership in Parabilis Medicines (PBLS) characterized?
Alan Sebulsky is the managing member of Apothecary Capital LLC and may share voting and investment power. However, he disclaims beneficial ownership of the LLC-held shares for Section 16 purposes, except to the extent of any pecuniary interest described.
AI-generated analysis. How Rhea-AI works. Not financial advice.
